Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
national top stories
13
×
boston top stories
clinical trials
biotech
san francisco blog main
new york blog main
new york top stories
amgen
boston
deals
fda
new york
san francisco top stories
alnylam pharmaceuticals
roche
sanofi
eli lilly
inclisiran
novartis
regeneron pharmaceuticals
san diego blog main
avapritinib
blueprint medicines
cancer
cancer drugs
cholesterol
genentech
hepatitis b
indiana blog main
indiana top stories
investing
medullary thyroid cancer
non-small cell lung cancer
patisiran
pcsk9
pcsk9 inhibitors
pralsetinib
What
drug
13
×
medicines
13
×
fda
genetic
new
approval
cancer
cholesterol
disease
ipo
medco
year
ago
announced
blueprint
company
diseases
hepatitis
latest
lowering
medicine
million
muscle
rare
research
ret
roche
team
therapeutics
twice
aces
acquire
address
adds
agreed
akcea
alliance
alnylam
amgen
amyloidosis
Language
unset
Current search:
medicines
×
drug
×
" national top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines